drugset / Trial / NCT05508373
A Clinical Study to Evaluate the Safety, Tolerability,JS019 in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of JS019 as monotherapy in patients with advanced malignant solid tumors The study includes JS019 monotherapy dose escalation, dose expansion stages to investigate the safety, tolerability, pharmacokinetics and preliminary anti-tumor efficacy of JS019 as monotherapy.
Timeline
- Start
- 2022-03-29
- Primary completion
- 2024-06-15
- Completion
- 2024-08-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JS019 | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | JS019 | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | JS019 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | JS019 | Monoclonal antibody | 10 mg/kg | Intravenous |